Genetic Risk for Inflammatory Bowel Disease Is a Determinant of Crohn's Disease Development in Chronic Granulomatous Disease

被引:41
作者
Huang, Chengrui [1 ]
Ravin, Suk See De [2 ]
Paul, Adam R. [3 ,4 ]
Heller, Theo [5 ]
Ho, Nancy [5 ]
Datta, Lisa Wu [4 ]
Zerbe, Christa S. [6 ]
Marciano, Beatriz E. [6 ]
Kuhns, Douglas B. [7 ]
Kader, Howard A. [3 ]
Holland, Steven M. [6 ]
Malech, Harry L. [2 ]
Brant, Steven R. [1 ,4 ]
机构
[1] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] NIAID, Lab Host Defenses, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[3] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA
[4] Johns Hopkins Univ, Sch Med, Dept Med, Meyerhoff Inflammatory Bowel Dis Ctr, Baltimore, MD 21205 USA
[5] NIDDK, NIH, Bethesda, MD 20892 USA
[6] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[7] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA
关键词
chronic granulomatous disease; inflammatory bowel disease; genetic risk score; immunodeficiency disorder; genetic interaction; STEM-CELL TRANSPLANTATION; COMPLICATIONS; POLYMORPHISMS; ASSOCIATION; CONSORTIUM; FEATURES; REGISTRY; GAMMA;
D O I
10.1097/MIB.0000000000000966
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Approximately, one-third to one-half of children with chronic granulomatous disease (CGD) develop gastrointestinal inflammation characteristic of idiopathic inflammatory bowel disease (IBD), usually Crohn's disease. We hypothesized that the overall IBD genetic risk, determined by IBD genetic risk score (GRS), might in part determine IBD development in CGD. Methods: We reviewed medical records to establish IBD diagnoses in CGD subjects seen at NIAID. IBD risk single nucleotide polymorphism genotypes were determined using the Immunochip, and GRS were estimated by Mangrove. Results: Among 157 white patients with CGD, 55 were confirmed, 78 excluded, and 24 were uncertain for IBD. Two hundred one established, independent European IBD risk single nucleotide polymorphisms passed quality control. After sample quality control and removing non-IBD CGD patients with perianal disease, mean GRS for 40 unrelated patients with CGD-IBD was higher than 53 CGD non-IBD patients (in log(2)-scale 0.08 +/- 1.62 versus -0.67 +/- 1.64, P = 0.026) but lower than 239 IBD Genetics Consortium (IBDGC) young-onset Crohn's disease cases (0.76 +/- 1.60, P = 0.025). GRS for non-IBD CGD was similar to 609 IBDGC controls (-0.69 +/- 1.60, P = 0.95). Seven established IBD single nucleotide polymorphisms were nominally significant among CGD-IBD versus CGD non-IBD, including those near LACC1 (P = 0.005), CXCL14 (P = 0.007), and TNFSF15 (P = 0.016). Conclusions: The weight of the common IBD risk alleles are significant determinants of IBD in CGD. However, IBD risk gene burden among CGD children with IBD is significantly lower than that in nonsyndromic pediatric Crohn's disease, congruent with the concept that defective superoxide production in CGD is also a major IBD risk factor. Individual IBD genes might interact with the CGD defect to cause IBD in CGD.
引用
收藏
页码:2794 / 2801
页数:8
相关论文
共 27 条
[1]  
Alimchandani M, 2013, AM J SURG PATHOL, V37, P1365, DOI 10.1097/PAS.0b013e318297427d
[2]   LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis [J].
Assadi, G. ;
Saleh, R. ;
Hadizadeh, F. ;
Vesterlund, L. ;
Bonfiglio, F. ;
Halfvarson, J. ;
Torkvist, L. ;
Eriksson, A. S. ;
Harris, H. E. ;
Sundberg, E. ;
D'Amato, M. .
GENES AND IMMUNITY, 2016, 17 (04) :261-264
[3]   Recent Insights Into the Genetics of Inflammatory Bowel Disease [J].
Cho, Judy H. ;
Brant, Steven R. .
GASTROENTEROLOGY, 2011, 140 (06) :1704-U21
[4]  
Clayton D., 2012, SNPSTATS SNPMATRIX X
[5]   Assessment of reliability and validity of IBD phenotyping within the national institutes of diabetes and digestive and kidney diseases (NIDDK) IBD genetics consortium (IBDGC) [J].
Dassopoulos, Themistocles ;
Nguyen, Geoffrey C. ;
Bitton, Alain ;
Bromfield, Gillian P. ;
Schumm, L. Philip ;
Wu, Yahong ;
Elkadri, Abdul ;
Regueiro, Miguel ;
Siemanowski, Benjamin ;
Torres, Esther A. ;
Gregory, Federico J. ;
Kane, Sunanda V. ;
Harrell, Laura E. ;
Franchimont, Denis ;
Achkar, Jean-Paul ;
Griffiths, Anne ;
Brant, Steven R. ;
Rioux, John D. ;
Taylor, Kent D. ;
Duerr, Richard H. ;
Silverberg, Mark S. ;
Cho, Judy H. ;
Steinhart, A. Hillary .
INFLAMMATORY BOWEL DISEASES, 2007, 13 (08) :975-983
[6]   Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease [J].
Foster, CB ;
Lehrnbecher, T ;
Mol, F ;
Steinberg, SM ;
Venzon, DJ ;
Walsh, TJ ;
Noack, D ;
Rae, J ;
Winkelstein, JA ;
Curnutte, JT ;
Chanock, SJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (12) :2146-2155
[7]   Itraconazole to prevent fungal infections in chronic granulomatous disease [J].
Gallin, JI ;
Alling, DW ;
Malech, HL ;
Wesley, R ;
Koziol, D ;
Marciano, B ;
Eisenstein, EM ;
Turner, ML ;
DeCarlo, ES ;
Starling, JM ;
Holland, SM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2416-2422
[8]  
Güngör T, 2014, LANCET, V383, P436, DOI [10.1016/s0140-6736(13)62069-3, 10.1016/S0140-6736(13)62069-3]
[9]   Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients [J].
Güngör, T ;
Halter, J ;
Klink, A ;
Junge, S ;
Stumpe, KDM ;
Seger, R ;
Schanz, U .
TRANSPLANTATION, 2005, 79 (11) :1596-1606
[10]   Special Article: Chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry [J].
Jones, L. B. K. R. ;
McGrogan, P. ;
Flood, T. J. ;
Gennery, A. R. ;
Morton, L. ;
Thrasher, A. ;
Goldblatt, D. ;
Parker, L. ;
Cant, A. J. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 152 (02) :211-218